Corporate Banner
Satellite Banner
Technology Networks Header
Saturday, November 01, 2014
Technology Networks
 
Register | Sign in
Home Page > Latest Webcasts
  Webcasts
Scientific News
MS Drug Candidate Shows Promise for Ulcerative Colitis
Positive new clinical data were released today on a drug candidate for ulcerative colitis that was first discovered and synthesized at The Scripps Research Institute.
New Technique has Profound Implications for Drug Development
The method, developed by Scripps Research Institute chemists, expands options for making pure batches of ‘one-handed’ molecules.
Team Discovers How Microbes Build a Powerful Antibiotic
Researchers discovery opens up new avenues of research into thousands of similar molecules.
Misfolded Proteins Clump Together in a Surprising Place
Stowers researchers create new framework for protein aggregation under acute stress.
Nanoparticle Research Could Enhance Drug Delivery Through Skin
A milestone study from the University of Southampton could have major implications for the delivery of drugs.
Chemists Recruit Anthrax to Deliver Cancer Drugs
With some tinkering, a deadly protein becomes an efficient carrier for antibody drugs.
Protein ‘Map’ Could Lead to Potent New Cancer Drugs
Findings will help scientists to design drugs that could target NMT enzyme.
Animal Testing can Mislead Drug Discovery and Development
Several blockbuster drugs would not be on the market, if scientists had relied solely on drug-uptake in animal trials, according to new research.
Synthesis and Bioactivity of Analogues of Tropodithietic Acid
The study suggests that the sulfur atoms in the marine antibiotic TDA are not essential for bioactivity, but different modes of action for TDA and its sulfur-free analogue cannot be excluded.
Cancer-Fighting Drugs Might Also Stop Malaria Early
A number of compounds have been identified which could be used to fight malaria.
Scroll Up
Scroll Down
Return
Chemogenomic Strategies to Expand the Bioactive Chemical Space
Edgar Jacoby, Group Leader, Novartis, speaking at MedChem Europe
Date Posted: Saturday, March 12, 2011
Print Page

For access to this article, enter your email address to instantly recieve a Password Reset link.

Please enter your email address below:

Existing users please Sign In here. Don't have an account? Register Here for free access.

Don't have an account? | Register Here



Novartis Provides Drug Candidate Compounds to TB Alliance
Exclusive worldwide license from Novartis includes a novel class of drugs that is active against drug sensitive and multi-resistant strains of tuberculosis.
Wednesday, August 20, 2014
Novartis Announces Portfolio Transformation
Company launches a major overhaul of its business, unveiling a series of multibillion-dollar deals with GSK and Eli Lilly.
Wednesday, April 23, 2014
Novartis and Collaborators Discover Novel Antimalarial Drug Candidate
New antimalarial drug candidate with novel mechanism of action has the potential to rapidly clear a Plasmodium infection upon administration of a single oral dose, as published in Science.
Tuesday, September 07, 2010
Novartis Gains Rights to Two Oral Targeted Investigational Therapies
Ex-US rights acquired for JAK inhibitor INCB18424 in Phase III development as first-in-class treatment for a life-threatening blood disorder.
Tuesday, December 01, 2009
Nuevolution Announces New Research Collaboration with Big Pharma
Partnership to use Nuevolution's Chemetics® technology for lead discovery.
Tuesday, September 01, 2009
Novartis Begins Shipment of Fluvirin® Seasonal Influenza Vaccine for U.S. Market Ahead of Schedule
Company is providing 30 million doses of Fluvirin vaccine to support the annual seasonal influenza vaccination campaign.
Thursday, August 06, 2009
FORMA Announces Collaboration with Novartis to Develop Inhibitors of Protein-Protein Interactions
FORMA will leverage its expertise to develop inhibitors for an undisclosed protein-protein interaction target in the field of oncology.
Tuesday, January 13, 2009
Dynavax Enters Into Supply and Option Agreement for Development of Universal Influenza Vaccine
Novartis will provide Dynavax a supply of trivalent influenza vaccine for both clinical trial use and vaccine sales.
Thursday, July 24, 2008
 
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv